Ondansetron Bluefish (Ondansetron BMM Pharma) Filmuhúðuð tafla 4 mg 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

ondansetron bluefish (ondansetron bmm pharma) filmuhúðuð tafla 4 mg

bluefish pharmaceuticals ab - ondansetronum hýdróklóríð - filmuhúðuð tafla - 4 mg

Ondansetron Bluefish (Ondansetron BMM Pharma) Filmuhúðuð tafla 8 mg 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

ondansetron bluefish (ondansetron bmm pharma) filmuhúðuð tafla 8 mg

bluefish pharmaceuticals ab - ondansetronum hýdróklóríð - filmuhúðuð tafla - 8 mg

Ondansetron STADA Filmuhúðuð tafla 8 mg 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

ondansetron stada filmuhúðuð tafla 8 mg

stada arzneimittel ag - ondansetronum hýdróklóríð - filmuhúðuð tafla - 8 mg

Ondansetron Fresenius Kabi Stungulyf, lausn 2 mg/ml 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

ondansetron fresenius kabi stungulyf, lausn 2 mg/ml

fresenius kabi ab - ondansetronum hýdróklóríð - stungulyf, lausn - 2 mg/ml

Ondansetron STADA Filmuhúðuð tafla 4 mg 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

ondansetron stada filmuhúðuð tafla 4 mg

stada arzneimittel ag - ondansetronum hýdróklóríð - filmuhúðuð tafla - 4 mg

Cinveron Stungulyf, lausn 2 mg/ml 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

cinveron stungulyf, lausn 2 mg/ml

williams & halls ehf - ondansetronum hýdróklóríð - stungulyf, lausn - 2 mg/ml

Zofran Filmuhúðuð tafla 4 mg 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

zofran filmuhúðuð tafla 4 mg

sandoz a/s - ondansetronum hýdróklóríð - filmuhúðuð tafla - 4 mg

Zofran Filmuhúðuð tafla 8 mg 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

zofran filmuhúðuð tafla 8 mg

sandoz a/s - ondansetronum hýdróklóríð - filmuhúðuð tafla - 8 mg

Zofran Mixtúra, lausn 0,8 mg/ml 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

zofran mixtúra, lausn 0,8 mg/ml

sandoz a/s - ondansetronum hýdróklóríð - mixtúra, lausn - 0,8 mg/ml

Vanflyta 유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

vanflyta

daiichi sankyo europe gmbh - quizartinib dihydrochloride - kyrningahvítblæði, mergbólga - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.